Rapamycin impairs HPD-induced beneficial effects on glucose homeostasis.

ABSTRACT:

Background and purpose

Rapamycin, which is used clinically to treat graft rejection, has also been proposed to have an effect on metabolic syndrome; however, very little information is available on its effects in lean animals/humans. The purpose of this study was to characterize further the effects of the continuous use of rapamycin on glucose homeostasis in lean C57BL6/J mice.

Experimental approach

Mice were fed a high-protein diet (HPD) for 12 weeks to develop a lean model and then were treated daily with rapamycin for 5 weeks while remaining on a HPD. Metabolic parameters, endocrine profiles, glucose tolerance tests, insulin sensitivity index, the expression of the glucose transporter GLUT4 and chromium distribution were measured in vivo.

Key results

Lower body wei

SUBMITTER: Chang GR 

PROVIDER: S-EPMC4523336 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature